title: Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.
abstract: The differential outcomes of clinical studies of the targeted therapies for non-small cell lung cancer (NSCLC) indicate that better stratification of patients is required. This could be achieved with the help of patient-derived xenografts (PDX) of epidermal growth factor receptor (EGFR) wild-type patients resistant to erlotinib treatment.
  
  
  
  To explore the potential of patient-derived NSCLC xenografts to optimize therapy using 24 well-characterized early-stage NSCLC PDX.
  
  
  
  Patient tumor tissue was transplanted subcutaneously into nude mice. After engraftment, tumors were expanded and the sensitivity was tested. Gene expression analysis was used to identify differentially expressed genes between erlotinib responder (n = 3) and non-responder (n = 21). Tumor tissue was analyzed with TaqMan PCR, immunohistochemistry and ELISA to examine the response of the models.
  
  
  
  Gene expression analysis revealed vascular endothelial growth factor A (VEGFA) to be up-regulated in erlotinib non-responder. Because of that, the combination of erlotinib with bevacizumab was evaluated in one erlotinib-sensitive and four erlotinib-resistant PDX. Combination treatment was superior to monotherapy, leading to the highest and significant inhibition of tumor growth in all models investigated. A decline of VEGFA protein and an increase of VEGFA-mRNA were observed after bevacizumab treatment. Bevacizumab treatment resulted in a distinct decrease of blood vessel number.
  
  
  
  This study showed that with the help of preclinical PDX models, drug combinations for therapy improvement can be identified on a rational basis. It was observed that a dual blockage of EGFR and VEGFA was more effective than a monotherapy for the treatment of NSCLC in selected PDX models. PDX could be employed to optimize the treatment of cancer patients.
authors.affiliation: Experimental Pharmacology & Oncology Berlin-Buch GmbH, Robert-Roessle-Str. 10, 13125, Berlin-Buch, Germany. j.rolff@epo-berlin.com.
authors.forename: J
authors.initials: J
authors.lastname: Rolff
authors.affiliation: Experimental Pharmacology & Oncology Berlin-Buch GmbH, Robert-Roessle-Str. 10, 13125, Berlin-Buch, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Becker
authors.affiliation: Labor Dr. Merk & Kollegen GmbH, Beim Braunland 1, 88416, Ochsenhausen, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Merk
authors.affiliation: Experimental Pharmacology & Oncology Berlin-Buch GmbH, Robert-Roessle-Str. 10, 13125, Berlin-Buch, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Hoffmann
authors.affiliation: Experimental Pharmacology & Oncology Berlin-Buch GmbH, Robert-Roessle-Str. 10, 13125, Berlin-Buch, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Fichtner
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000068258:Bevacizumab / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015870:Gene Expression / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009367:Neoplasm Staging; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride
references.citation: Growth Factors. 1992;7(1):53-64
references.pmid: 1380254
references.citation: Lancet Oncol. 2014 Oct;15(11):1236-44
references.pmid: 25175099
references.citation: Clin Cancer Res. 2008 Oct 15;14(20):6456-68
references.pmid: 18927285
references.citation: Cancer Res. 2000 Dec 15;60(24):7075-83
references.pmid: 11156414
references.citation: Cancer Res. 2000 Sep 15;60(18):5117-24
references.pmid: 11016638
references.citation: Mol Cancer Ther. 2010 Jul;9(7):1931-44
references.pmid: 20571071
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: Cancer Res. 2006 Mar 15;66(6):3197-204
references.pmid: 16540671
references.citation: Clin Cancer Res. 1999 Feb;5(2):257-65
references.pmid: 10037173
references.citation: Clin Cancer Res. 2009 May 15;15(10 ):3484-94
references.pmid: 19447865
references.citation: Br J Cancer. 2010 May 25;102(11):1555-77
references.pmid: 20502460
references.citation: Clin Lung Cancer. 2009 Mar;10 Suppl 1:S17-23
references.pmid: 19362942
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2544-55
references.pmid: 15753462
references.citation: Hematol Oncol Clin North Am. 2004 Oct;18(5):1007-21, viii
references.pmid: 15474332
references.citation: Cancer Res. 2010 Dec 1;70(23):9886-94
references.pmid: 21118974
references.citation: Nat Rev Cancer. 2008 Aug;8(8):579-91
references.pmid: 18596824
references.citation: Cancer Res. 1997 Oct 15;57(20):4593-9
references.pmid: 9377574
references.citation: Eur J Cancer. 2010 Mar;46(4):765-81
references.pmid: 20116997
references.citation: Clin Lung Cancer. 2006 Jan;7(4):250-6
references.pmid: 16512978
references.citation: Cancer Cell. 2004 Dec;6(6):553-63
references.pmid: 15607960
references.citation: Cancer Res. 2009 Apr 15;69(8):3364-73
references.pmid: 19351829
references.citation: Cell. 2010 Jan 22;140(2):268-79
references.pmid: 20141840
references.citation: PLoS One. 2011;6(11):e27514
references.pmid: 22087332
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references.pmid: 15329413
references.citation: Cancer Cell. 2007 Jan;11(1):83-95
references.pmid: 17222792
references.citation: J Clin Oncol. 2013 Nov 1;31(31):3926-34
references.pmid: 24101054
references.citation: Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2197-207
references.pmid: 16609035
references.citation: Br J Cancer. 2003 Jun 16;88(12 ):1979-86
references.pmid: 12799646
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Cancer Res. 2004 Jun 1;64(11):3731-6
references.pmid: 15172975
references.citation: Cancer Treat Rev. 2012 May;38(3):173-84
references.pmid: 21715100
references.citation: Eur J Cancer. 2002 May;38(8):1133-40
references.pmid: 12008203
references.citation: Nat Clin Pract Oncol. 2008 Sep;5(9):521-30
references.pmid: 18594498
references.citation: N Engl J Med. 2005 Jul 14;353(2):123-32
references.pmid: 16014882
references.citation: Curr Ther Res Clin Exp. 2009 Apr;70(2):116-28
references.pmid: 24683223
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: PLoS Med. 2005 Jan;2(1):e17
references.pmid: 15696205
references.citation: Clin Lung Cancer. 2007 Feb;8 Suppl 2:S79-85
references.pmid: 17382029
references.citation: Microarrays (Basel). 2013 Dec 13;2(4):318-39
references.pmid: 27605195
references.citation: Lung Cancer. 2013 Nov;82(2):276-81
references.pmid: 23992877
references.citation: Med Oncol. 2015 Feb;32(2):473
references.pmid: 25603953
references.citation: J Clin Oncol. 2013 Mar 10;31(8):1061-9
references.pmid: 23401452
references.citation: Cancer Chemother Pharmacol. 2014 Dec;74(6):1297-305
references.pmid: 25344762
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: Pharmacol Ther. 2011 Jul;131(1):80-90
references.pmid: 21439312